Hermon Eyob Fesseha
Research Subjects
Hermon Eyob Fesseha has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mohammadreza Shoghli
Population Health, University of Helsinki Faculty of Medicine, Helsinki, Finland
3 shared publications - Siyamak Jalal Hosseini3 shared publications
Yosan Eyob
2 shared publications- Alexandra Häme1 shared publication
- Laura Sundell1 shared publication
- Laura Sundell1 shared publication
Latest Publications
- 28 July 2025
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 2 (2) , 52-57
Right Ventricular Infarction Following Inferior STEMI: A Case Report and Comprehensive Review of Management Challenges
Right ventricular infarction (RVI) is a life-threatening complication of inferior ST-elevation myocardial infarction (STEMI), occurring in approximately 30–50% of such cases—typically when the proximal right coronary artery (RCA) is occluded [1,2]. While left ventricular (LV) infarction receives more clinical focus, RVI significantly worsens patient outcomes and is often underdiagnosed due to nonspecific signs [3,4]. The right ventricle (RV) is anatomically distinct from the LV, with a thinner free wall, lower systolic pressure, and greater dependence on preload. These characteristics make the RV highly susceptible to ischemic damage and volume depletion. RV dysfunction can compromise left-sided output due to interventricular dependence, thereby leading to systemic hypotension and cardiogenic shock [5,6]. Although timely revascularization is the cornerstone of STEMI therapy, standard management strategies may be inadequate in dominant RVI. In such cases, mechanical support such as right ventricular assist devices (RVADs) or extracorporeal membrane oxygenation (ECMO) can be lifesaving. Unfortunately, these are not universally accessible, particularly in resource-limited settings [7]. We present a case of inferior STEMI with RVI, highlighting the limitations of current management and the impact of unavailable mechanical RV support.
- 28 July 2025
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 2 (2) , 52-57
Right Ventricular Infarction Following Inferior STEMI: A Case Report and Comprehensive Review of Management Challenges
Right ventricular infarction (RVI) is a life-threatening complication of inferior ST-elevation myocardial infarction (STEMI), occurring in approximately 30–50% of such cases—typically when the proximal right coronary artery (RCA) is occluded [1,2]. While left ventricular (LV) infarction receives more clinical focus, RVI significantly worsens patient outcomes and is often underdiagnosed due to nonspecific signs [3,4]. The right ventricle (RV) is anatomically distinct from the LV, with a thinner free wall, lower systolic pressure, and greater dependence on preload. These characteristics make the RV highly susceptible to ischemic damage and volume depletion. RV dysfunction can compromise left-sided output due to interventricular dependence, thereby leading to systemic hypotension and cardiogenic shock [5,6]. Although timely revascularization is the cornerstone of STEMI therapy, standard management strategies may be inadequate in dominant RVI. In such cases, mechanical support such as right ventricular assist devices (RVADs) or extracorporeal membrane oxygenation (ECMO) can be lifesaving. Unfortunately, these are not universally accessible, particularly in resource-limited settings [7]. We present a case of inferior STEMI with RVI, highlighting the limitations of current management and the impact of unavailable mechanical RV support.
- 28 July 2025
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 2 (2) , 45-51
Chronic Reactive Arthritis Following Bacillus Calmette-Guérin (BCG) Instillations: A Case Report and Review
Background: Reactive arthritis (ReA) is an inflammatory joint condition that typically develops days to weeks after a gastrointestinal or genitourinary infection. While it is often associated with a classic triad of arthritis, urethritis, and conjunctivitis, many patients may not exhibit all three symptoms. Previously known as “Reiter syndrome,” named after Hans Reiter, ReA is thought to result from an abnormal autoimmune response to infections caused by pathogens such as Salmonella, Shigella, Campylobacter, or Chlamydia. Recognizing this connection is essential for effective diagnosis and treatment. Case Description: A 67-year-old male developed reactive arthritis (ReA) following intravesical Bacillus Calmette-Guérin (iBCG) therapy for non-muscle invasive bladder cancer. Elevated inflammatory markers and a negative HLA-B27 result were noted. The symptoms were attributed to iBCG-related ReA, leading to the discontinuation of iBCG treatment. Outcome: Initial treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids was ineffective, necessitating disease-modifying antirheumatic drugs (DMARDs) for sustained remission and symptom control. Although chronic arthritis requiring prolonged DMARD therapy is uncommon, the patient required over 1.5 years of DMARD treatment to manage symptoms effectively. Keywords: iBCG intravesical Bacillus Calmette-Guérin, DMARD disease-modifying antirheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs
- 28 July 2025
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 2 (2) , 45-51
Chronic Reactive Arthritis Following Bacillus Calmette-Guérin (BCG) Instillations: A Case Report and Review
Background: Reactive arthritis (ReA) is an inflammatory joint condition that typically develops days to weeks after a gastrointestinal or genitourinary infection. While it is often associated with a classic triad of arthritis, urethritis, and conjunctivitis, many patients may not exhibit all three symptoms. Previously known as “Reiter syndrome,” named after Hans Reiter, ReA is thought to result from an abnormal autoimmune response to infections caused by pathogens such as Salmonella, Shigella, Campylobacter, or Chlamydia. Recognizing this connection is essential for effective diagnosis and treatment. Case Description: A 67-year-old male developed reactive arthritis (ReA) following intravesical Bacillus Calmette-Guérin (iBCG) therapy for non-muscle invasive bladder cancer. Elevated inflammatory markers and a negative HLA-B27 result were noted. The symptoms were attributed to iBCG-related ReA, leading to the discontinuation of iBCG treatment. Outcome: Initial treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids was ineffective, necessitating disease-modifying antirheumatic drugs (DMARDs) for sustained remission and symptom control. Although chronic arthritis requiring prolonged DMARD therapy is uncommon, the patient required over 1.5 years of DMARD treatment to manage symptoms effectively. Keywords: iBCG intravesical Bacillus Calmette-Guérin, DMARD disease-modifying antirheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs
- 28 December 2024
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 1 (3) , 11-17
Post-Pericardiotomy Syndrome Following Mitral Valve Replacement Surgery in a Patient with Rheumatic Fever: A Case Report
Background: Post-cardiac injury syndrome (PCIS) is an inflammatory condition triggered by immune responses following cardiac injury. PCIS encompasses post-myocardial pericarditis, post-pericardiotomy syndrome (PPS), and post-traumatic pericarditis, whether iatrogenic or not. In this case report, we describe a patient who developed PPS after undergoing mitral valve replacement surgery. Case presentation: A young African woman with mitral stenosis caused by rheumatic fever underwent successful mitral valve replacement surgery. Approximately one month later, she developed post-pericardiotomy syndrome, which was subsequently diagnosed and treated. The patient initially presented to the hospital with exertional dyspnoea, and echocardiography revealed severe mitral stenosis, leading to the scheduling of surgery. While awaiting the procedure, she developed atrial fibrillation (AF) and congestive heart failure. In 2022, she underwent mitral valve replacement surgery and was discharged one week later after experiencing a smooth recovery. Two weeks after discharge, she visited the emergency department due to shortness of breath, but no concerning signs were found upon examination. She was prescribed diuretics and discharged. One week later, she was admitted to the hospital again due to chest pain, dyspnoea, and an elevated C-reactive protein (CRP) level of 123. Echocardiography and chest computed tomography (CT) scans were normal. She was treated with antibiotics under suspicion of pneumonia and subsequently discharged. Ten days later, she returned to the emergency department with high fever, chest pain, and dyspnea, and her CRP level had risen to 240. Echocardiography revealed no signs of endocarditis or pericardial effusion. Considering the patient's surgical history and frequent hospitalizations for similar symptoms, PPS was suspected. The patient was administered a first-line treatment of colchicine 0.5mg once a day. As a result, CRP levels decreased, fever and chest pain resolved, and she was discharged in a stable condition. A month later she was re-admitted to the hospital due to PPS relapse, Colchicine dose was elevated to 1mg a day and was discharged in good condition. Colchicine was planned to be continued for six months. Conclusion: PPS is a common complication following open-heart surgery, characterized by a generally mild course but with the potential for severe complications. Treatment typically involves anti-inflammatory agents, aspirin, and colchicine. The recurrence rate is approximately 10-15%. Early diagnosis and treatment of PPS can minimize frequent hospitalizations and reduce the need for extensive testing
- 28 December 2024
- Published by Jain Hospital & Research Centre in Diabetes Asia Journal
- Vol. 1 (3) , 11-17
Post-Pericardiotomy Syndrome Following Mitral Valve Replacement Surgery in a Patient with Rheumatic Fever: A Case Report
Background: Post-cardiac injury syndrome (PCIS) is an inflammatory condition triggered by immune responses following cardiac injury. PCIS encompasses post-myocardial pericarditis, post-pericardiotomy syndrome (PPS), and post-traumatic pericarditis, whether iatrogenic or not. In this case report, we describe a patient who developed PPS after undergoing mitral valve replacement surgery. Case presentation: A young African woman with mitral stenosis caused by rheumatic fever underwent successful mitral valve replacement surgery. Approximately one month later, she developed post-pericardiotomy syndrome, which was subsequently diagnosed and treated. The patient initially presented to the hospital with exertional dyspnoea, and echocardiography revealed severe mitral stenosis, leading to the scheduling of surgery. While awaiting the procedure, she developed atrial fibrillation (AF) and congestive heart failure. In 2022, she underwent mitral valve replacement surgery and was discharged one week later after experiencing a smooth recovery. Two weeks after discharge, she visited the emergency department due to shortness of breath, but no concerning signs were found upon examination. She was prescribed diuretics and discharged. One week later, she was admitted to the hospital again due to chest pain, dyspnoea, and an elevated C-reactive protein (CRP) level of 123. Echocardiography and chest computed tomography (CT) scans were normal. She was treated with antibiotics under suspicion of pneumonia and subsequently discharged. Ten days later, she returned to the emergency department with high fever, chest pain, and dyspnea, and her CRP level had risen to 240. Echocardiography revealed no signs of endocarditis or pericardial effusion. Considering the patient's surgical history and frequent hospitalizations for similar symptoms, PPS was suspected. The patient was administered a first-line treatment of colchicine 0.5mg once a day. As a result, CRP levels decreased, fever and chest pain resolved, and she was discharged in a stable condition. A month later she was re-admitted to the hospital due to PPS relapse, Colchicine dose was elevated to 1mg a day and was discharged in good condition. Colchicine was planned to be continued for six months. Conclusion: PPS is a common complication following open-heart surgery, characterized by a generally mild course but with the potential for severe complications. Treatment typically involves anti-inflammatory agents, aspirin, and colchicine. The recurrence rate is approximately 10-15%. Early diagnosis and treatment of PPS can minimize frequent hospitalizations and reduce the need for extensive testing